A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Inclusion Criteria:

- Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop
on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG)
criteria

- Subject has relapsed/refractory disease with an indication for treatment

- Subject has refractory disease or developed recurrence after therapy with a BCR PI

- Subject must have an Eastern Cooperative Oncology Group performance score of equal to
or less than 2

- Subject must have adequate bone marrow function at Screening

- Subject must have adequate coagulation profile, renal, and hepatic function, per
laboratory reference range at Screening

Exclusion Criteria:

- Subject has undergone an allogeneic stem cell transplant within the past year

- Subject has developed Richter's transformation confirmed by biopsy

- Subject has active and uncontrolled autoimmune cytopenia

- Subject has malabsorption syndrome or other condition that precludes enteral route of
administration

- Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or
hepatitis C virus requiring treatment

- Subject has known contraindication or allergy to both xanthine oxidase inhibitors and
rasburicase.